Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy

NCT02819557 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT02819557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02819557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Lead sponsor
PTC Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2016
Completion date
February 9, 2018
Enrollment
14 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy